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Artichoke and milk thistle pills and syrups as sources
of phenolic compounds with antimicrobial activity
Carla Pereira,a Lillian Barros,*a,b Maria José Alves,c Celestino Santos-Buelgad and
Isabel C. F. R. Ferreira*a
Dietary supplements based on hepatoprotective plants have been increasingly used in the prevention of
liver injuries. In the present work, the aim was to study the phenolic proﬁle and possibly relate it to the
in vitro antimicrobial activity of two diﬀerent formulations (pills and syrups) of artichoke and milk thistle,
the antioxidant and anti-hepatocellular carcinoma activities of which were previously reported by our
research group. The phenolic proﬁles were obtained by HPLC-DAD-ESI/MS, and the antimicrobial activity
evaluation was performed with the clinical isolates of multiresistant bacteria (Escherichia coli, extended
spectrum β-lactamases (ESBL) producing Escherichia coli, Proteus mirabilis, methicillin-resistant Staphylo-
coccus aureus (MRSA) and Pseudomonas aeruginosa). Artichoke syrup revealed the presence of vanillic
acid and luteolin-7-O-glucoside while the pills possessed higher concentrations of 4-O-caﬀeoylquinic,
5-O-caﬀeoylquinic and 1,3-O-dicaﬀeoylquinic acids, this latest being able to inhibit the growth of MRSA.
Regarding milk thistle formulations, the syrup presented isorhamnetin-O-deoxyhexoside-O-dihexoside, iso-
rhamnetin-O-deoxyhexoside-O-hexoside and isorhamnetin-3-O-rutinoside as the major phenolic constitu-
ents whereas the pills were richer in taxifolin, silymarin derivatives and hydroxylated silibinin; the syrup
revealed antimicrobial activity against all the studied bacteria with the exception of Proteus mirabilis whereas
the pills revealed activity against ESBL producing Escherichia coli. Overall, all of the studied formulations
revealed to be a good source of phenolic compounds, among which milk thistle syrup presented the highest
variety and concentration of ﬂavonoids, which is possibly related to its strongest antimicrobial activity.
1. Introduction
Microbial infections have become a major threat to public
health, and are considered as one of the leading causes of
morbidity and mortality throughout the world, especially in
developing countries.1 With the increased microorganisms’
antibiotic resistance natural products have been explored for
their antimicrobial properties as an alternative and/or in com-
bination with conventional antibiotics in order to achieve
synergistic eﬀects.2,3 Medicinal plants, with the particular
abundance of phytochemicals such as phenolic compounds
became an invaluable trump in the line of medicine, among
which artichoke (Cynara scolymus L.) and milk thistle (Silybum
marianum (L.) Gaertn) are two herbs with several therapeutic
applications and are also described as good sources of flavo-
noids and phenolic acids.4,5 In previous studies, extracts from
these plants and their isolated phenolic compounds proved to
be able to inhibit the growth of several bacterial strains, which
led some authors to conclude that their antimicrobial capacity
can be attributed to their phenolic composition. For instance,
the hydroalcoholic extracts of artichoke leaves showed activity
against Escherichia coli and Salmonella abony enterica,6 and phe-
nolic extracts from its hearts and bracts against Escherichia coli,
Pseudomonas aeruginosa, Staphylococcus aureus, Bacillus subtilis,
Aspergillus niger and Candida albicans.7 On the other hand, milk
thistle seed extracts were eﬀective against Escherichia coli, Sta-
phylococcus sprophyticus, Staphylococcus aureus, and Klebsiella
pneumoniae,8 while silymarin and silibinin, characteristic
phenolic compounds of milk thistle, inhibited Escherichia coli,
Pseudomonas aeruginosa, and Staphylococcus aureus.9
Nowadays, with the tremendous development of the dietary
supplements industry, herbal formulations based on these
and many other medicinal plants are available in various for-
mulations such as dry material for infusion preparation, pills,
capsules, syrups, lotions, ampoules, etc.10 Nevertheless, scarce
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studies have been conducted in order to clarify the diﬀerences
between the phenolic composition and bioactivity of such for-
mulations, and in this framework, the present study aimed to
provide complementary scientific information regarding
dietary supplements (pills and syrups) based on artichoke and
milk thistle that previously proved to possess antioxidant and
anti-hepatocellular carcinoma activities.11,12 For this purpose,
phenolic characterization was performed by HPLC-DAD-ESI/
MS, and the in vitro antimicrobial activity evaluation was per-
formed against the clinical isolates of multiresistant bacteria
(Escherichia coli, extended spectrum β-lactamases (ESBL) pro-
ducing Escherichia coli, Proteus mirabilis, methicillin-resistant
Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa)
obtained from the Hospital Center of Trás-os-Montes and Alto
Douro (CHTMAD, Chaves, Portugal).
2. Materials and methods
2.1. Samples
Cynara scolymus L. (artichoke) and Silybum marianum (L.)
Gaertn (milk thistle) were obtained from an herbalist shop in
Bragança (Portugal), as pills and syrups. According to the label
information, the pills contain an agglutinative (modified corn
starch), a diluent (microcrystalline cellulose), an anti-agglomera-
tion agent (dibasic calcium phosphate anhydrous and silicon
dioxide), a lubricant (magnesium stearate), and 500 mg of arti-
choke or milk thistle plant dry extract, for each case. The syrups
are composed of 100% of artichoke, water and preservative
(methyl p-hydroxybenzoate); and 2.3% of milk thistle, sea buck-
thorn, carriers (fructose, water), sweetener (sorbitol), thickening
agents (guar and locust bean gum), preservative (potassium
sorbate), acidifier (L-ascorbic acid), and stabilizer (pectin).
2.2. Standards and reagents
HPLC-grade acetonitrile was obtained from Merck KgaA
(Darmstadt, Germany). Formic acid was purchased from
Prolabo (VWR International, Fontenay-sous-Bois, France). Phe-
nolic standards were from Extrasynthèse (Genay, France).
Water was treated using a Milli-Q water purification system
(TGI Pure Water Systems, Greenville, SC, USA). Methanol was
of analytical grade purity from Lab-Scan (Lisbon, Portugal).
The culture media Mueller Hinton Broth (MHB), Wilkins–
Chalgren broth (WCB) and Columbia agar (CA) with 5% horse
blood were obtained from Biomerieux (Marcy l’Etoile, France).
The dye p-iodonitrotetrazolium chloride (INT) was purchased
from Sigma-Aldrich (St Louis, MO, USA) to be used as a
microbial growth indicator.
2.3. Characterization in phenolic compounds
2.3.1. Extraction procedures. The pills (1.5 g) were ground
to powder and subjected to hydromethanolic extraction by stir-
ring with 25 mL of methanol : water (80 : 20 v/v, 25 °C at 150
rpm) for 1 h and subsequently filtered through Whatman no.
4 paper. The residues were then extracted with an additional
25 mL of methanol : water (80 : 20 v/v) for another hour. The
combined extracts were dried (Büchi R-210, Flawil, Switzer-
land) and purified using a C18 SepPak® Vac 3 cc cartridge
(Phenomenex), previously activated with methanol followed by
water; sugars and more polar substances were removed by
passing 10 mL of water through the cartridge and the purified
samples were further eluted with 5 mL of methanol. The
extracts were concentrated under vacuum.
The artichoke syrup (5 mL) was subjected to purification
following the procedure described above and then concen-
trated under vacuum. Regarding the milk thistle syrup, due to
its consistency, it was extracted and purified following the pro-
cedure described for the pills, the obtained extract was then
concentrated under vacuum.
2.3.2. Analysis of phenolic compounds. The previously
described extracts were dissolved in water : methanol (80 : 20,
v/v) to the final concentrations of 3 and 59 mg mL−1 for the
pills and 7 and 16 mg mL−1 for the syrups of artichoke and
milk thistle, respectively. The analysis was performed using a
Hewlett-Packard 1100 chromatograph (Hewlett-Packard 1100,
Agilent Technologies, Santa Clara, CA, USA) with a quaternary
pump and a diode array detector (DAD) coupled to an HP
Chem Station (rev. A.05.04) data-processing station. A Waters
Spherisorb S3 ODS-2 C18, 3 μm (4.6 mm × 150 mm) column
thermostatted at 35 °C was used. The solvents were (A) 0.1%
formic acid in water, and (B) acetonitrile. The elution gradient
established was isocratic 15% for 5 min, 15% B to 20% B over
5 min, 20–25% B over 10 min, 25–35% B over 10 min, 35–50%
for 10 min, and re-equilibration of the column, using a flow
rate of 0.5 mL min−1. Double online detection was carried out
in the DAD using 280 nm and 370 nm as the preferred wave-
lengths and in a mass spectrometer (MS) connected to the
HPLC system via the DAD cell outlet.
MS detection was performed using an API 3200 Qtrap
(Applied Biosystems, Darmstadt, Germany) equipped with an
ESI source and a triple quadrupole-ion trap mass analyzer that
was controlled by using the Analyst 5.1 software. Zero grade air
served as the nebulizer gas (30 psi) and turbo gas for solvent
drying (400 °C, 40 psi). Nitrogen served as the curtain (20 psi)
and collision gas (medium). The quadrupoles were set at unit
resolution. The ion spray voltage was set at −4500 V in the nega-
tive mode. The MS detector was programmed for recording in
two consecutive modes: enhanced MS (EMS) and enhanced
product ion (EPI) analysis. EMS was employed to record full
scan spectra, so as to obtain an overview of all of the ions in the
sample. The settings used were: declustering potential (DP)
−450 V, entrance potential (EP) −6 V, and collision energy (CE)
−10 V. The EPI mode was performed in order to obtain the frag-
mentation pattern of the parent ion(s) in the previous scan
using the following parameters: DP −50 V, EP −6 V, CE −25 V,
and collision energy spread (CES) 0 V. Spectra were recorded in
negative ion mode between m/z 100 and 1500.
The phenolic compounds were identified by comparing
their retention time, UV-vis and mass spectra with those
obtained from standard compounds, when available. Other-
wise, compounds were tentatively identified by comparing the
obtained information with the available data reported in the
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literature. For quantitative analysis, a calibration curve for each
available phenolic standard was constructed based on the UV
signal. For the identified phenolic compounds for which a
commercial standard was not available, the quantification was
performed using the calibration curve of other compounds
from the same phenolic group. The results were expressed in
µg per g of lyophilized extract. For each formulation, the ana-
lyses were carried out in triplicate.
2.4. Evaluation of antimicrobial activity
2.4.1. Sample preparation. The pills were ground to
powder and dissolved in distilled water to a final concentration
of 150 mg mL−1. The syrups were directly used in the concen-
trations of 1000 and 26 mg mL−1, according to the label
information.
2.4.2. Antimicrobial activity assays. To screen the anti-
microbial activity, the used microorganisms were clinical iso-
lates from patients hospitalized in various departments of the
Hospital Center of Trás-os-Montes and Alto Douro (Vila Real,
Portugal). Four Gram-negative bacteria (Escherichia coli iso-
lated from urine, extended spectrum β-lactamases (ESBL) pro-
ducing Escherichia coli isolated from blood culture, Proteus
mirabilis isolated from wound exudates and Pseudomonas aeru-
ginosa isolated from urine) and one Gram-positive bacterium
(methicillin-resistant Staphylococcus aureus (MRSA) isolated
from wound exudates) were used. Microorganism’s identifi-
cation and susceptibility tests were performed using Micro-
Scan panels (MicroScan®; Siemens Medical Solutions
Diagnostic, West Sacramento, CA, USA) by the microdilution
plate method. The interpretation criteria were based on inter-
pretative breakpoints as indicated in EUCAST (European Com-
mittee on Antimicrobial Susceptibility Testing)13 and Clinical
and Laboratory Standards Institute (CLSI) document M100-
S1814 and the report of the Committee of L’Antibiogramme de la
Société Française de Microbiologie (CA-SFM).15
Minimum inhibitory concentration (MIC) determinations
were performed by the microdilution method and the rapid
p-iodonitrotetrazolium chloride (INT) colorimetric assay follow-
ing the methodology previously described by Alves et al.16
Initially, 50 µL of each extract was diluted in 450 μL of MHB
(final concentration of 15 mg mL−1 for the pills; 100 and
2.6 mg mL−1 for the syrups of artichoke and milk thistle, respec-
tively) and then, 200 μL of this extract solution was added in each
well (96-well microplate). Dilutions were carried out over the wells
with 100 μL of MHB and, afterwards, 10 μL of inoculum (1.5 ×
108 CFU mL−1) were added to all the wells. Three negative con-
trols were prepared with MHB, extract, bacterium and antibiotics.
Tobramycin and vancomycin were used for Gram negative and
positive bacteria, respectively, at concentrations according to the
obtained MIC values (Tables 1 and 2). A positive control was also
prepared with MHB and the inoculum. The plates were incu-
bated at 37 °C, for 24 h, in an oven (Jouan).
The MICs of the samples were determined after adding
40 μL of INT (0.2 mg mL−1) and incubating at 37 °C for
30 min. Viable microorganisms reduced the yellow dye to a
pink color. MIC was defined as the lowest extract concen-
tration that prevented this change and exhibited inhibition of
bacterial growth. All the assays were carried out in duplicate.
3. Results and discussion
3.1. Phenolic compounds
Tables 3 and 4 present the data obtained from HPLC-DAD-MS
analysis (retention time, λmax in the visible region, mass spec-
Table 1 MIC values (µg ml−1) of diﬀerent antibiotics against Gram negative bacteria
E. coli
ESBL producing
E. coli P. mirabilis P. Aeruginosa
Ampicillin >16 R ≥32 R ≤8 S Na
Amoxicillin/clavulanic acid 16/8 R ≥16/8 R ≤8/4 S Na
Cephalothin 8 S ≥64 R ≤8 S Na
Cefazolin ≤8 S na ≤8 S Na
Cefuroxime ≤4 S ≥64 R ≤4 S Na
Cefoxitin ≤8 S na ≤8 S na
Cefotaxime ≤1 S ≥64 R ≤1 S 16 R
Ceftazidime ≤1 S 4 I ≤1 S 2 S
Cefepime 16 S na ≤1 S 4 S
Nalidíxic acid >16 R na >16 R na
Norfloxacin >8 R na 4 S na
Ciprofloxacin >2 R ≥4 R >2 R ≤0.5 S
Nitrofurantoin ≤32 S 64 S >64 R na
Fosfomycin ≤16 S na >64 R na
Gentamicin ≤2 S ≤1 S 8 I > 8 R
Imipenem ≤1 S na 2 S ≤1 S
Piperacilin/Tazobactam ≤8 S ≤4 S ≤8 S ≤8 S
Trimethoprim/Sulfasoxazole ≤2/38 S ≥320 R >4/76 R 4/76 R
Tobramycin ≤2 S ≤1 S 4 S 4 S
S – susceptible; I – intermediate; R – resistant (this classification was made according to the interpretative breakpoints suggested by the Clinical
and Laboratory Standards Institute – CLSI and European Committee on Antimicrobial Susceptibility Testing (EUCAST)); na – not applicable.
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tral data) used for the identification and quantification of phe-
nolic compounds in artichoke and milk thistle formulations.
The phenolic compounds identified in artichoke formu-
lations obviously showed similarities to the infusions and
hydroalcoholic extracts previously analysed by our research
group,5 all the detected compounds being already described
and tentatively identified, with the exception of peaks 2A, 8A
and 16A. Compound 2A was positively identified as vanillic
acid, according to its retention time, mass and UV-vis charac-
teristics by comparison with a commercial standard. To the
best of our knowledge, vanillic acid has not been described in
artichoke, thus it might be present in the syrup due to its
addition as a flavouring agent, even though it was not men-
tioned on the label. Compounds 8A and 16A were tentatively
identified as 4-O-caﬀeoylquinic acid and 3,4-O-dicaﬀeoylquinic
acid, respectively, taking into account the fragmentation pat-
terns reported by Cliﬀord et al.17,18 and previous identifi-
cations in other materials in our laboratory.19–21
Diﬀerent monocaﬀeoylquinic and dicaﬀeoylquinic acids in
diﬀerent parts of artichoke have been widely reported by many
authors.22–31 The syrup did not contain this type of compound,
but showed apigenin and luteolin derivatives, which are also
very characteristic of artichoke (with the exception of vanillic
acid), with luteolin-7-O-glucoside being the most abundant
compound. The main compounds present in the pills were
chlorogenic acid (i.e., 5-O-caﬀeoylquinic acid) and cynarin (i.e.,
1,3-O-dicaﬀeoylquinic acid); these molecules are also the most
characteristic compounds found in artichoke. The absence of
cynarin in the syrup (Table 3) could be explained by its depen-
dence on the part of the plant used (information not provided on
Table 2 MIC values (µg ml−1) of diﬀerent antibiotics against Gram posi-
tive bacteria
MRSA MRSA
Penicillin >8 Blac Ciprofloxacin >2 R
Ampicillin >8 Blac Levofloxacin >4 R
Cefoxitin Screen >4 Pos Linezolid 2 S
Oxacillin >2 R Synercid 1 S
Clindamycin 1 I Teicoplanin 2 S
Daptomycin ≤0.5 S Tetracycline ≤1 S
Erythromycin ≤0.25 S Trimethoprim/
Sulfasoxazole
≤1/19 S
Fosfomycin ≤32 S Vancomycin 2 S
Gentamicin 4 S
S – susceptible; I – intermediate; R – resistant (this classification was
made according to the interpretative breakpoints suggested by the
Clinical and Laboratory Standards Institute – CLSI and European
Committee on Antimicrobial Susceptibility Testing (EUCAST)); Blac –
Beta-lactamase positive; Pos – positive to cefoxitin screening; Neg –
negative to cefoxitin screening; na – not applicable.
Table 3 Retention time (Rt), wavelengths of maximum absorption in the visible region (λmax), mass spectral data, identiﬁcation and quantiﬁcation of
phenolic compounds in syrup and pill formulations of artichoke (mean ± SD)
Compound
Rt
(min)
λmax
(nm)
Molecular ion
[M − H]− (m/z) MS2 (m/z) Tentative identification
Quantification
(µg g−1)
Syrup
1A 14.1 338 607 269(100) Apigenin-O-hexoside-O-glucuronide 0.29 ± 0.01
2A 15.5 264, 296sh 167 123(100) Vanillic acid 5.58 ± 0.02
3A 19.7 350 461 285(100) Luteolin-7-O-glucoronide 0.72 ± 0.04
4A 20.6 354 447 285(100) Luteolin-7-O-glucoside 2.2 ± 0.1
5A 25.1 336 431 269(100) Apigenin-7-O-glucoside 0.49 ± 0.02
Total phenolic acids 5.58 ± 0.02
Total flavonoids 3.7 ± 0.1
Total phenolic compounds 9.3 ± 0.1
Pill
6A 5.2 326 353 191(100), 179(82), 135(73) 3-O-Caﬀeoylquinic acid 1.854 ± 0.005
7A 5.6 324 341 179(85), 135(100) Caﬀeic acid hexoside 2.0 ± 0.1
8A 7.2 328 353 191(59), 179(64), 173(100),
161(10), 135(77)
4-O-Caﬀeoylquinic acid 13.3 ± 0.3
9A 7.9 328 353 191(100), 179(32), 173(20),
161(6), 135(12)
5-O-Caﬀeoylquinic acid 28.2 ± 0.7
10A 11.4 324 179 135(100) Caﬀeic acid 1.7 ± 0.2
11A 12.4 324 515 353(85), 335(11), 191(100),
179(90), 173(6), 161(12), 135(49)
1,3-O-Dicaﬀeoylquinic acid 24 ± 1
1A 14.5 334 607 431(43), 269(43) Apigenin-O-hexoside-O-glucuronide 1.36 ± 0.06
13A 17.1 312 163 119(100) p-Coumaric acid 0.041 ± 0.009
14A 19.6 350 593 285(100) Luteolin-7-O-rutinoside 1.37 ± 0.07
3A 20.3 348 461 285(100) Luteolin-7-O-glucuronide 2.59 ± 0.08
16A 20.7 326 515 353(49), 335(17), 191(47), 179(58),
173(83), 161(22), 135(46)
3,4-O-Dicaﬀeoylquinic acid 6.1 ± 0.1
17A 22.7 326 515 353(31), 335(10), 191(100),
179(20), 161(8), 135(5)
3,5-O-Dicaﬀeoylquinic acid 7.1 ± 0.1
5A 25.0 332 445 269(100) Apigenin-7-O-glucuronide 3.07 ± 0.05
Total phenolic acids 85 ± 3
Total flavonoids 8.4 ± 0.3
Total phenolic compounds 93 ± 2
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the label), with some studies reporting that artichoke heads have
lower contents of cynarin than the leaves or floral stems.25,32
In contrast to artichoke, both the formulations of milk
thistle hardly presented similarities to the infusions and
hydroalcoholic extract previously described,5 with the excep-
tion of compounds 1MT (5-O-caﬀeolyquinic acid) and 17MT
(3-O-caﬀeolyquinic acid), that were both identified.5 In the litera-
ture, milk thistle phenolic composition is characterized by the
presence of a mixture of flavonolignans (silymarin), which are
known to be normally present in its seeds.33–43 Nevertheless,
the syrup formulation presented flavonol derivatives, mainly
isorhamnetin, quercetin and kaempferol glycoside derivatives,
as the main compounds, with the exception of compound 9MT,
that was positively identified as p-coumaric acid, according to
its retention time, mass and UV-vis characteristics by compari-
son with commercial standards, and compound 1MT (5-O-
caﬀeolyquinic acid).
Compounds 3MT,4MT,6MT,10MT, 11MT, 12MT, 13MT,14MT,15MT
and 16MT were identified as isorhamnetin derivatives owing to
the product ion observed at m/z 315 and the UV spectra (λmax
around 352–358 nm). Compounds 14MT (isorhamnetin-3-O-
rutinoside) and 16MT (isorhamnetin-3-O-glucoside) were posi-
tively identified by comparison with commercial standards.
Peaks 3MT and 6MT presented the same pseudomolecular ion
Table 4 Retention time (Rt), wavelengths of maximum absorption in the visible region (λmax), mass spectral data, identiﬁcation and quantiﬁcation of
phenolic compounds in syrup and pill formulations of milk thistle (mean ± SD)
Compound
Rt
(min) λmax (nm)
Molecular ion
[M − H]− (m/z) MS2 (m/z) Tentative identification
Quantification
(µg g−1)
Syrup
1MT 8.0 326 353 191(100), 179(20), 173(10),
135(8)
5-O-Caﬀeolyquinic acid 1.90 ± 0.02
2MT 11.4 350 771 625(50), 301(33) Quercetin-O-deoxyhexoside-O-dihexoside 0.73 ± 0.02
3MT 12.5 352 785 623(100), 315(33) Isorhamnetin-O-hexoside-O-rutinoside 0.60 ± 0.02
4MT 12.8 356 639 477(58), 315(57) Isorhamnetin-O-hexoside-O-hexoside 1.13 ± 0.07
5MT 14.0 350 755 609(100), 285(36) Kaempferol-O-deoxyhexoside-O-dihexoside 1.55 ± 0.02
6MT 14.6 356 785 639(100), 315(26) Isorhamnetin-O-deoxyhexoside-O-dihexoside 3.64 ± 0.04
7MT 15.7 358 755 301(100) Quercetin-O-deoxyhexoside-rutinoside 0.33 ± 0.02
8MT 16.5 358 609 463(13), 447(33), 301(13) Quercetin-3-O-rutinoside 0.33 ± 0.03
9MT 17.3 310 163 119(100) p-Coumaric acid 0.39 ± 0.03
10MT 19.4 358 769 623(72), 461(16), 315(28) Isorhamnetin-O-deoxyhexoside-O-rutinoside 2.25 ± 0.07
11MT 19.9 354 623 477(50), 461(37), 315(75) Isorhamnetin-O-deoxyhexoside-O-hexoside 7.26 ± 0.04
12MT 22.0 356 593 461(33), 315(33) Isorhamnetin-O-pentosyl-O-deoxyhexoside 0.26 ± 0.02
13MT 23.1 354 623 315(100) Isorhamnetin-O-deoxyhexoside-hexoside 0.69 ± 0.03
14MT 23.7 356 623 315(100) Isorhamnetin-3-O-rutinoside 5.75 ± 0.04
15MT 24.9 356 477 315(100) Isorhamnetin-O-hexoside 0.59 ± 0.02
16MT 25.2 354 477 315(100) Isorhamnetin-3-O-glucoside 1.21 ± 0.02
Total phenolic acids 2.30 ± 0.01
Total flavonoids 26.3 ± 0.4
Total phenolic compounds 28.6 ± 0.4
Pill
17MT 5.3 326 353 191(100), 179(60), 173(5),
135(80)
3-O-Caﬀeolyquinic acid 0.020 ± 0.001
1MT 8.0 328 353 191(100), 179(60), 173(35),
135(26)
5-O-Caﬀeolyquinic acid 0.0314 ± 0.0001
18MT 12.4 328 515 353(44), 191(100), 179(56),
173(5), 161(33), 135(56)
1,3-O-Caﬀeolyquinic acid 0.049 ± 0.002
19MT 19.3 290 336sh 303 285(97), 259(15), 241(15),
217(12), 199(21), 177(38),
150(15), 125(100)
Taxifolin 0.284 ± 0.007
20MT 25.2 286 481 463(10), 453(10), 337(5),
325(5), 301(8), 299(10),
283(5), 179(13), 151(23),
125(10)
Silymarin derivative 0.131 ± 0.005
21MT 28.8 288 481 463(10), 453(14), 337(10),
325(10), 179(43), 151(19),
125(48)
Silymarin derivative 0.27 ± 0.02
22MT 29.2 278 481 463(5), 453(20), 301(8),
299(3), 283(3), 179(38),
151(30), 125(24)
Silymarin derivative 0.33 ± 0.01
23MT 29.6 290 481 463(7), 453(12), 325(3),
301(7), 179(24), 169(17),
153(17), 151(19), 125(17)
Silymarin derivative 0.12 ± 0.02
24MT 30.6 284 336sh 497 453(86), 435(57), 317(71),
181(57), 151(28), 125(29)
Hydroxylated silibinin 1.565 ± 0.007
Total phenolic acids 0.1003 ± 0.0005
Total flavonoids 2.70 ± 0.06
Total phenolic compounds 2.80 ± 0.06
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[M − H]− at m/z 785, but revealed a diﬀerent MS2 fragmenta-
tion pattern. Compound 3MT presented the consecutive losses
of hexosyl (product ion at m/z 623; −162 u) and deoxyhexosyl-
hexoside (ion at m/z 315; −308 u), while peak 6MT presented
the losses of deoxyhexosyl (m/z at 639; −146 u) and dihexosyl
(m/z at 315; −324 u). For both the peaks, no information about
the identity of the sugar moieties and their location in the
aglycone could be obtained, so these compounds were tenta-
tively identified as isorhamnetin-O-hexoside-O-(deoxyhexosyl-
hexoside) and isorhamnetin-O-deoxyhexoside-O-dihexoside,
respectively. Moreover, the positive identification of diﬀerent
rutinosides, including isorhamnetin-3-O-rutinoside, in the
analyzed sample may suggest a rutinose identity for the deoxy-
hexosyl-hexose residue present in peak 3MT. Similarly, peak 10 MT
([M − H]− at m/z 769) was assigned to isorhamnetin-O-deoxy-
hexoside-O-rutinoside. The mass characteristics of compound
4MT ([M − H]− at m/z 639) indicated that it corresponds to an
isorhamnetin derivative bearing two hexosyl residues. The
observation of MS2 fragments at m/z 477 (−162 u) and 315
(−162 u), also indicated the consecutive loss of each of the
hexosyl moieties, pointing to their location on diﬀerent posi-
tions of the aglycone. Thus, this compound was tentatively
identified as isorhamnetin-O-hexosyl-O-hexoside. Moreover,
peaks 11MT and 13MT presented the same pseudomolecular
ion as compound 14MT (isorhamnetin-3-O-rutinoside), indicat-
ing that they should correspond to other isorhamnetin deriva-
tives bearing deoxyhexosyl and hexosyl residues. Nevertheless,
the fragmentation pattern of compound 11MT, with the alterna-
tive losses of the deoxyhexosyl (ion at m/z 477) and hexosyl (ion
at m/z 461) moieties indicated that the sugars were located on
diﬀerent positions of the aglycone, whereas in compound
13MT, for which only one ion at m/z 315 corresponding to the
aglycone was produced, the two sugars residues should consti-
tute a disaccharide. Thus, these compounds were tentatively
assigned as isorhamnetin-O-deoxyhexosyl-O-hexoside (peak
11MT) and isorhamnetin-O-deoxyhexosyl-hexoside (peak 13MT).
This later could correspond to an isorhamnetin O-neohesperi-
doside or to an O-rutinoside bearing the sugar residue on a
location diﬀerent to peak 14MT (isorhamnetin-3-O-rutinoside).
Following a similar reasoning, peak 12MT ([M − H]− at m/z 593)
was assigned to isorhamnetin-O-pentosyl-O-deoxyhexoside,
and peak 15MT ([M − H]− at m/z 477) to an isorhamnetin-O-
hexoside diﬀering from peak 15MT (isorhamnetin-3-O-gluco-
side) in the type of sugar or the position of substitution.
Peaks 2MT, 7MT and 8MT were identified as quercetin glyco-
sides based on their UV spectra (λmax around 358 nm) and the
production of an MS2 fragment ion at m/z 301. Similarly, peak
5MT was identified as a kaempferol glycoside (λmax around
348 nm, MS2 fragment at m/z 285). Tentative identities of these
compounds were assigned based on their pseudomolecular
ions using a similar reasoning to that for isorhamnetin deriva-
tives. Thus, peaks 2MT ([M − H]− at m/z 771) and 5MT ([M − H]−
at m/z 639) could correspond to quercetin-O-deoxyhexoside-O-
dihexoside and kaempferol-O-deoxyhexoside-O-dihexoside,
respectively, whereas peak 7MT ([M − H]− at m/z 755) was
tentatively assigned as quercetin-O-hexoside-O-rutinoside.
Compound 8MT was positively identified as quercetin-3-O-
rutinoside according to its retention time, mass and UV-vis
characteristics by comparison with a commercial standard.
The pills of milk thistle showed the presence of five (peaks
20MT, 21MT, 22MT, 23MT and 24MT) flavonolignans (silymarin),
assigned based on their UV spectra (λmax around 286-290 nm),
the observation of the ion at m/z 481 and a very characteristic
fragmentation pattern observed in many studies.33–43 Never-
theless, due to the lack of commercial standards and diﬃculty
in interpreting fragmentation, the complete identification of
these compounds was not possible, and therefore they were
characterized as silymarin derivatives. These compounds were
quantified using a taxifolin calibration curve. Compound 24MT
was identified as a hydroxylated silibinin taking into account
its pseudomolecular ion, 16 u higher than peaks 20MT–23MT,
and the findings of Venisetty et al.44 Finally, peak 18MT (1,3-O-
caﬀeolyquinic acid) was identified taking into account the
retention time and fragmentation pattern observed for com-
pound 11A, and peak 19MT was positively identified as taxifolin
according to its retention, mass and UV-vis characteristics by
comparison with a commercial standard.
Isorhamnetin-O-deoxyhexoside-O-hexoside and isorhamne-
tin-O-rutinoside were the main phenolic compounds in milk
thistle syrup, while hydroxyl silybin was the most prominent
compound in the pills.
3.2. Antimicrobial activity
The screening of the antimicrobial activity of artichoke and
milk thistle was performed using the diﬀerent formulations
(pills and syrups) and the results are presented in Table 5.
Among the artichoke-based samples, only the pills revealed
antimicrobial activity, inhibiting the growth of MRSA with a
MIC value of 1.9 mg mL−1. In contrast to the results obtained
by Alves et al.,45 where vanilic acid inhibited the growth of
Escherichia coli and Proteus mirabilis, among others, the syrup
of artichoke, which contained the referenced acid, did not
inhibit the bacterial growth of the studied cultures, which
might be due to its low concentration in the sample.
Regarding milk thistle, the syrup presented the highest
antimicrobial activity, with lower MIC values, and proved to be
able to inhibit the growth of Escherichia coli, ESBL producing
Escherichia coli, MRSA and Pseudomonas aeruginosa, with MIC
values ranging from 0.2 to 1.3 mg mL−1. The pills showed anti-
microbial activity for Escherichia coli ESBL at 15 mg mL−1, but
did not inhibit the growth of the remaining bacteria. Among
Table 5 Antimicrobial activity of pills and syrups of artichoke and milk
thistle against bacterial clinical isolates (MIC values, mg mL−1)
Bacteria
Artichoke Milk thistle
Pills Syrup Pills Syrup
Escherichia coli >15 >100 >15 0.3
Escherichia coli ESBL >15 >100 15 0.2
Proteus mirabilis >15 >100 >15 >2.6
MRSA 1.9 >100 >15 0.2
Pseudomonas aeruginosa >15 >100 >15 1.3
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the studied formulations of these plants, none of them was
able to inhibit Proteus mirabilis at the studied concentrations.
As far as we know, there are no reports on the antimicrobial
activity of pills or syrups containing artichoke or milk thistle,
although there are studies performed with hydroalcoholic
extracts of artichoke, which exhibited antimicrobial activity
against Escherichia coli and Salmonella abony enterica.6 More-
over, Zhu et al.46 performed a study using several fractions
obtained from artichoke leaves, showing that at least six kinds
of bacteria were sensitive to these extracts, including Bacillus
subtilis, Staphylococcus aureus, Agrobacterium tumefaciens,
Micrococcus luteus, Escherichia coli, and Salmonella typhimur-
ium. On the other hand, ethanolic extracts from milk thistle
seeds revealed antimicrobial activity in several clinical bac-
terial isolates, such as Escherichia coli, Staphylococcus aureus,
Staphylococcus saprophyticus, and Klebsiella pneumoniae when
mixed with agar media.8 Furthermore, several compounds iso-
lated from artichoke also showed antimicrobial activity against
microbial strains, including some of the bacteria used in the
present study, namely Escherichia coli, Staphylococcus aureus,
and Pseudomonas aeruginosa.46 One of the compounds isolated
and tested by Zhu et al.46 that revealed antimicrobial activity
was 3,5-O-dicaﬀeoylquinic acid, found in the pills of artichoke
studied herein, which could explain its antimicrobial activity;
the same observation can be made for luteolin and apigenin
derivatives that were present in this formulation. p-Coumaric
acid (detected in the pills and syrup of artichoke and in the
syrup of milk thistle) was tested by Lou et al.47 and revealed
activity against Escherichia coli, Staphylococcus aureus, Salmo-
nella typhimurium, and Shigella dysenteriae; nonetheless, in the
present study not all of the formulations containing this mole-
cule presented antimicrobial activity. On the other hand, Cetin-
Karaca and Newman48 reported the antimicrobial capacity of
5-O-caﬀeoylquinic acid against Escherichia coli and several other
microbial cultures, which might justify the activity of the syrup
of milk thistle that contained this molecule. The antimicrobial
capacity of the milk thistle pills could also be related to the
presence of silibinin and silymarin, which revealed this kind of
activity in a study performed with Escherichia coli, Staphylo-
coccus aureus, and Pseudomonas aeruginosa.9
Overall, the studied formulations were found to be a good
source of phenolic compounds. Milk thistle syrup presented the
highest variety of these phytochemicals with sixteen diﬀerent
compounds identified and the highest concentration of flavo-
noids, which could possibly explain its potent antimicrobial
activity. Nonetheless, the remaining formulations were also able
to inhibit some of the studied bacterial strains and also proved
to be rich in phenolic compounds, among which artichoke pills
showed the highest concentration of phenolic acids.
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